United States· US:0310-9501_78f077b9-49c8-47f6-8950-1799764a5dd4
TRUQAP
A medicinal product containing capivasertib, registered in United States by AstraZeneca Pharmaceuticals LP.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- capivasertib
- Manufacturer
- AstraZeneca Pharmaceuticals LP
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- June 3, 2026
Packs & prices · 3
- ndc11031095010164 TABLET, FILM COATED in 1 BOTTLE (0310-9501-01)
- ndc1103109501024 BLISTER PACK in 1 CARTON (0310-9501-02) / 16 TABLET, FILM COATED in 1 BLISTER PACK
- ndc1103109501964 BLISTER PACK in 1 CARTON (0310-9501-96) / 16 TABLET, FILM COATED in 1 BLISTER PACK
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Capivasertib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandTruqap 200 mg, FilmtablettenAstraZeneca AG
- CzechiaTRUQAPAstraZeneca AB, Södertälje
- SpainTRUQAP 200 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAstrazeneca Ab
- FinlandTRUQAPAstraZeneca AB
- IrelandTRUQAP 200 mg film-coated tabletsAstraZeneca AB
- BelgiumTruqap 200 mgAstraZeneca
- NetherlandsTRUQAP 200 mg filmomhulde tablettenAstraZeneca AB
- NorwayTruqapAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Truqap
- Liechtenstein · Truqap
- Norway · Truqap
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/079cbaa4-ddbb-4457-9bea-05bc04754401 GET /v1/drugs/079cbaa4-ddbb-4457-9bea-05bc04754401?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"productid": "0310-9501_78f077b9-49c8-47f6-8950-1799764a5dd4",
"productndc": "0310-9501",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "CAPIVASERTIB",
"proprietary_name": "TRUQAP",
"active_ingred_unit": "mg/1",
"application_number": "NDA218197",
"marketing_category": "NDA",
"nonproprietary_name": "capivasertib",
"start_marketing_date": "20231116",
"active_numerator_strength": "200"
}See everything about capivasertib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.